Furthermore, we miss information on patients who chose to undergo RRSs due to pathogenic variants in other high-risk genes such as TP53, STK11, PTEN, PALB2, and CDH1 or after pedigree-based BC risk assessment. This evidence concerns the gene PALB2 and breast cancer.